等待开盘 11-06 09:30:00 美东时间
-1.720
-0.50%
今日重点评级关注:Citizens:维持Precigen"跑赢大市"评级,目标价从11美元升至12美元;Leerink Partners:维持Arcus Biosciences"跑赢大市"评级,目标价从46美元升至49美元
今天 16:15
FactSet and Hamilton Lane announce a strategic partnership to integrate Hamilton Lane's private markets data into FactSet's portfolio analytics platform, enabling unified analysis of public and private portfolios. The collaboration addresses the need for comprehensive tools to evaluate and manage multi-asset class investments, offering proprietary benchmarking, enhanced risk models, and whole portfolio monitoring. This partnership aims to empower...
11-02 14:01
Major US indices pulled back this week, even as earnings season pointed to strong performance by American companies. The S&P 500 dropped to 7,623, its lowest level since October 1 and 2.8% below its peak for the year. The tech-heavy Nasdaq 100 tumbled to 28,957, down 7.5% from its year-to-date high....
10-25 03:45
华盛资讯10月20日讯,慧甚公布2026财年年度业绩,公司年度营收24.76亿美元,同比增长6.7%,归母净利润5.33亿美元,同比下滑10.6%。
10-20 19:45
BMO Capital analyst Jeffrey Silber maintains FactSet Research Systems (NYSE:FDS) with a Market Perform and raises the price target from $300 to $314.
10-14 01:19
FactSet与Scotia Wealth Management扩大合作,整合其统一研究和情报平台,提升顾问体验和客户价值。Scotia Wealth Management的顾问将获得投资研究、市场数据、组合分析等资源,帮助他们为客户提供更优质的服务。双方高管对合作表示满意,认为这将增强各自的竞争力和客户价值。这一举措突显了FactSet作为财富管理首选平台的地位,同时也巩固了Scotiabank在科技工具方面的高标准。
10-08 13:01
The S&P 500 Index has wavered and is hovering near its all-time high. The next few weeks could be important as top companies report earnings and the odds of a Federal Reserve rate hike decline. The index ended the week at 7,722 points, slightly below its record of 7,817. Wall Street Analysts Are Bra...
10-04 01:30
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• # FactSet 2026财年第四季度及全年业绩回顾摘要 ## 1. 财务业绩 **第四季度业绩(FY2026 Q4):** - **营收(Revenue)**:6.347亿美元,报告口径同比增长6.3%,有机增长7.1%,由广泛的需求驱动 - **调整后营业利润(Adjusted Operating Income)**:2.09亿美元,调整后营业利润率为33% - **调整后摊薄每股收益(Adjusted Diluted EPS, non-GAAP)**:4.52美元,同比增长11.6% - **有机ASV(年度订阅价值)增量**:8600万美元
10-02 12:32
今日重点评级关注:Ascendiant Capital:维持NRX Pharmaceuticals"买入"评级,目标价从49美元升至50美元;Ascendiant Capital:维持Atossa Therapeutics"买入"评级,目标价从24美元升至25美元
10-02 08:33